Skip to main content

previous disabled Page of 3
and
  1. Article

    Open Access

    Predictive value for cerebrospinal fluid Alzheimer's disease profile of different measures of verbal episodic memory in patients with MCI

    Neuropsychological evidence of memory impairment represents the main feature of the clinical onset of typical Alzheimer’s disease (AD). Rey’s Auditory Verbal Learning Test (RAVLT) and Logical Memory (LM) are t...

    Nicola Salvadori, Edoardo Guido Torrigiani, Federico Paolini Paoletti in Scientific Reports (2024)

  2. No Access

    Article

    Hyposmia correlates with axial signs and gait disorder in Parkinson’s disease: an Italian Olfactory Identification Test study

    Olfactory dysfunction is a non-motor symptom and an important biomarker of Parkinson’s disease (PD) because of its high prevalence (> 90%). Whether hyposmia correlates with motor symptoms is unclear. In the pr...

    Nicola Tambasco, Alessandro Mechelli, Pasquale Nigro in Neurological Sciences (2024)

  3. Article

    Open Access

    Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum

    Alzheimer’s disease (AD) cerebrospinal fluid (CSF) core biomarkers (Aβ42/40 ratio, p-tau, and t-tau) provide high diagnostic accuracy, even at the earliest stage of disease. However, these markers do not fully...

    Silvia Paciotti, Anna Lidia Wojdała, Giovanni Bellomo in Alzheimer's Research & Therapy (2023)

  4. Article

    Open Access

    Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer’s disease: an expert opinion and practical guideline

    No disease-modifying therapies are currently available for Alzheimer’s disease (AD) in Europe. Current evidence from clinical trials testing anti-beta amyloid (Aβ) monoclonal antibodies (mAbs) in patients with...

    Massimo Filippi, Giordano Cecchetti, Annachiara Cagnin in Journal of Neurology (2023)

  5. Article

    Open Access

    CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment

    Pathophysiological substrate(s) and progression of Parkinson’s disease (PD) with mild cognitive impairment (PD-MCI) are still matter of debate. Baseline cerebrospinal fluid (CSF) neurochemical profile and cogn...

    Federico Paolini Paoletti, Lorenzo Gaetani, Giovanni Bellomo in npj Parkinson's Disease (2023)

  6. Article

    Open Access

    Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays

    Aggregation of α-synuclein (α-syn) is a prominent feature of Parkinson’s disease (PD) and other synucleinopathies. Currently, α-syn seed amplification assays (SAAs) using cerebrospinal fluid (CSF) represent th...

    Giovanni Bellomo, Silvia Paciotti, Luis Concha-Marambio in Molecular Neurodegeneration (2023)

  7. Article

    Open Access

    Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

    Itziar de Rojas, Sonia Moreno-Grau, Niccolo Tesi in Nature Communications (2023)

  8. Article

    Open Access

    Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease

    Proenkephalin (PENK) and prodynorphin (PDYN) are peptides mainly produced by the striatal medium spiny projection neurons (MSNs) under dopaminergic signaling. Therefore, they may represent candidate biomarkers...

    Peggy Barschke, Samir Abu-Rumeileh, M. H. D. Rami Al Shweiki in Journal of Neurology (2022)

  9. Article

    Open Access

    Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem)

    Dementia with Lewy bodies (DLB) may represent a diagnostic challenge, since its clinical picture overlaps with other dementia. Two toolkits have been developed to aid the clinician to diagnose DLB: the Lewy Bo...

    Mirella Russo, Claudia Carrarini, Angelo Di Iorio in Neurological Sciences (2022)

  10. No Access

    Article

    The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI

    Measures to define treatment response, such as no evidence of disease activity (NEDA), are routinely used in multiple sclerosis (MS) clinical practice. Although spinal cord involvement is a frequent feature of...

    Elena Di Sabatino, Lorenzo Gaetani, Silvia Sperandei, Andrea Fiacca in Journal of Neurology (2022)

  11. Article

    Open Access

    New insights into the genetic etiology of Alzheimer’s disease and related dementias

    Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We per...

    Céline Bellenguez, Fahri Küçükali, Iris E. Jansen, Luca Kleineidam in Nature Genetics (2022)

  12. Article

    Open Access

    PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study

    Reducing percutaneous endoscopic gastrostomies with jejunal extension tubes (PEG-J) related complications is vital to the long-term preservation of duodenal levodopa infusion (DLI) in advanced Parkinson’s dise...

    Simone Simoni, Pasquale Nigro, Marta Filidei, Giulia Cappelletti in BMC Neurology (2022)

  13. No Access

    Article

    Small-expanded allele spinocerebellar ataxia 17: imaging and phenotypic variability

    Spinocerebellar ataxia 17 (SCA17) is a rare genetic cause of adult-onset ataxia caused by an abnormal expansion of the CAG/CAA sequence in the TATA-box Binding Protein (TBP) gene. A number of repeats higher than ...

    Federico Paolini Paoletti, Paolo Prontera, Pasquale Nigro in Neurological Sciences (2021)

  14. No Access

    Article

    Amyloid-β: a potential link between epilepsy and cognitive decline

    People with epilepsy — in particular, late-onset epilepsy of unknown aetiology — have an elevated risk of dementia, and seizures have been detected in the early stages of Alzheimer disease (AD), supporting the...

    Michele Romoli, Arjune Sen, Lucilla Parnetti, Paolo Calabresi in Nature Reviews Neurology (2021)

  15. Article

    Open Access

    A multicentre validation study of the diagnostic value of plasma neurofilament light

    Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 1...

    Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat in Nature Communications (2021)

  16. Article

    Open Access

    Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

    Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curat...

    Itziar de Rojas, Sonia Moreno-Grau, Niccolo Tesi in Nature Communications (2021)

  17. No Access

    Article

    High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer’s disease

    Altered glutamatergic neurotransmission is thought to play a crucial role in the progression of Alzheimer’s disease (AD). Accordingly, the identification of peculiar biochemical patterns reflecting AD-related ...

    Tommaso Nuzzo, Andrea Mancini, Mattia Miroballo, Alessia Casamassa in Amino Acids (2021)

  18. No Access

    Article

    Changes of olfactory tract in Parkinson’s disease: a DTI tractography study

    Impaired olfactory function is one of the main features of Parkinson’s disease. However, how peripheral olfactory structures are involved remains unclear. Using diffusion tensor imaging fiber tracking, we inve...

    Pasquale Nigro, Andrea Chiappiniello, Simone Simoni in Neuroradiology (2021)

  19. Article

    Open Access

    Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?

    Cerebrospinal fluid (CSF) amyloid-beta (Aβ) 42/40 ratio, threonine-181-phosphorylated-tau (p-tau), and total-tau (t-tau) represent core biomarkers of Alzheimer disease (AD). The recent availability of automate...

    Giovanni Bellomo, Samuela Cataldi, Silvia Paciotti in Alzheimer's Research & Therapy (2020)

  20. No Access

    Article

    The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up

    Cognitive Function Instrument (CFI) is a questionnaire aimed at detecting very early changes in cognitive and functional abilities and useful for monitoring cognitive decline in individuals without clinical im...

    Elena Chipi, Chiara Montanucci, Paolo Eusebi, Katia D’Andrea in Neurological Sciences (2019)

previous disabled Page of 3